Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

Blood

Volumn 112, Issue 8, 2008, Pages 3303-3311

  De Groot, Anne S ^a,b   Moise, Leonard ^a   McMurry, Julie A ^a   Wambre, Erik ^c   Van Overtvelt, Laurence ^c   Moingeon, Philippe ^c   Scott, David W ^d   Martin, William ^a  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c Stallergenes SA   (France)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CELL SURFACE MARKER; EPITOPE; IMMUNOGLOBULIN FC FRAGMENT; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HOUSE DUST ALLERGY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE DEPLETION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; CYTOLOGY; EPITOPE MAPPING; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; METABOLISM; MITE; MONONUCLEAR CELL; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; EPITOPE MAPPING; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, TRANSGENIC; MITES; T-LYMPHOCYTES, REGULATORY;

EID: 54049088585     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-138073     Document Type: Article

References (40)

1. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253-257.
2. Umetsu DT, DeKruyff RH. The regulation of allergy and asthma. Immunol Rev. 2006;212:238-255.
3. Karlsson MR, Rugtveit J, Brandtzaeg P. Allergenresponsive CD4+CD25 + regulatory T cells in children who have outgrown cow's milk allergy. J Exp Med. 2004;199:1679-1688.
4. * 0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci U S A. 2006;103: 11683-11688.
5. Sumida T, Kato T, Hasunuma T, Maeda T, Nishioka K. Matsumoto I. Regulatory T cell epitope recognized by T cells from labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum. 1997;40:2271-2273.
6. Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol. 1996;157:1037-1046.
7. Phillips WJ, Smith DJ, Bona CA, Bot A, Zaghouani H. Recombinant immunoglobulinbased epitope delivery: a novel class of autoimmune regulators. Int Rev Immunol. 2005;24:501-517.
8. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatoryT cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008;111:715-722.
9. National Center for Biotechnology Information. GenBank. http://www.ncbi.nlm.nih.gov/Genbank/. Accessed August 30, 2008.
10. De Groot AS, Bishop EA, Khan B, et al. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods. 2004;34: 476-487.
11. Koita OA, Dabitao D, Mahamadou I, et al. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum Vaccin. 2006;2:119-128.
12. McMurry J, Sbai H, Gennaro ML, Carter EJ, Martin W, De Groot AS. Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis (Edinb). 2005;85:95-105.
13. McMurry JA, Gregory SH, Moise L, Rivera D, Buus S, De Groot AS. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine. 2007;25:3179-3191.
14. Reijonen H, Kwok W. Use of HLA class II tetramers in tracking antigen-specific T-cells and mapping T-cell epitopes. Methods. 2003;29:282-288.
15. Knopf PM, Rivera DS, Hai SH, McMurry J, Martin W, De Groot AS. Novel function of complement C3d as an autologous helper T-cell target. Immunol Cell Biol. 2008;86:221-225.
16. Van Overtvelt L, Wambre E, Maillère B, et al. Assessment of Bet v 1-specific CD4+ T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers. J Immunol. 2008;180:4514-4522.
17. *0401) transgenic mice expressing an altered CD4-binding site: specificity and magnitude of DR4-restricted T cell response. J Immunol. 1998;161:2925-2929.
18. Tosello V, Odunsi K. Souleimanian NE, et al. Differential expression of CCR7 defines two distinct subsets of human memory CD4+CD25+ Tregs. Clin Immunol. 2008;126:291-302.
19. Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J Immunol. 1999;162:1278-1286.
20. D'Ambrosio D, lellem A, Bonecchi R. Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol. 1998;161:5111-5115.
21. + T cells and protection in airway allergy models. Vaccine. 2005;23:3181-3186.
22. Borel Y. Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev. 1980;50:71-104.
23. Baxevanis CN, loannides CD, Reclos GJ, Papamichail M. Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function. Eur J Immunol. 1986;16:1013-1016.
24. Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci U S A. 1996;93:5019-5024.
25. El-Amine M, Melo M, Kang Y, Nguyen H, Qian J, Scott DW. Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells. J Immunol 2000;165: 5631-5636.
26. Kang Y, Melo M, Deng E. Tisch R, El-Amine M, Scott DW. Induction of hyporesponsiveness to intact multi-determinant foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immunologic hyporesponsiveness. Proc Natl Acad Sci U S A. 1999;96:8609-8614.
27. El-Amine M, Hinshaw JA, Scott DW. In vivo induction of tolerance by an Ig peptide is not affected by the deletion of FcR or a mutated IgG Fc fragment. Int Immunol. 2002;14:761-766.
28. Lei TC, Scott DW. Induction of tolerance to fVIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B-cells as Ig fusion proteins. Blood. 2005;105:4865-4870.
29. Soukhareva N, Jiang Y, Scott DW. Role of regulatory T cells in B-cell delivered gene therapy for the treatment of diabetes. Cell Immunol. 2006; 240:41-46.
30. Watier H. Variability factors in the clinical response to recombinant antibodies and IgG Fccontaining fusion proteins. Expert Opin Biol Ther. 2005;5(suppl 1):S29-S36.
31. Bluestone JA, Abbas AK. Nature reviews. Immunology. 2003;3:253-257.
32. Joshi T, Ganesan LP, Cao X, Tridandapani S. Molecular analysis of expression and function of hFc Rllbl and b2 isoforms in myeloid cells. Mol Immunol. 2006;43:839-850.
33. Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc Natl Acad Sci U S A. 2002;99:7588-7593.
34. Abrahamson DR, Rodewald R. Evidence for the sorting of endocytic vesicle contents during the receptor-mediated transport of IgG across the newborn rat intestine. J Cell Biol. 1981;91:270-280.
35. Telemo E, Jakobsson I, Westrom BR, Folkesson H. Maternal dietary antigens and the immune response in the offspring of the guinea-pig. Immunology. 1987;62:35-38.
36. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol. 2007;179:5571-5575.
37. Jordan SC, Vo AA, Peng A, Toyoda M, Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant. 2006;6:459-466.
38. Colagiuri S, Leong GM, Thayer Z, et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol. 1996; 14(suppl 15):S93-S97.
39. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 suppl):S525-S553.
40. Soelberg Sorensen P. Intravenous polyclonal human immunoglobulins in multiple sclerosis. Neurodegener Dis. 2008;5:8-15.